1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Orient Pharma Co., Ltd.

Orient Pharma Co., Ltd.

TTPEX:4166
23.70
TWD
-0.10
(-0.42%)
0.40EPS
65.20P/E
6.33BMarket Cap
Nov 17Next Earn
Orient Pharma Co., Ltd.
TPEX:4166
(Taipei Exchange)

Recent

price

23.70

P/E

ratio

65.20

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
0.83
0.82
0.89
1.07
1.38
0.9
2.02
1.67
1.72
2.27
2.43
2.48
2.74
3.99
5.48
6.08
3.15
Revenue per Share
-0.95
-1.35
-1.16
-1.04
-0.86
-1.4
-1.46
-1.93
-1.02
-1.29
-1.01
-0.55
-0.15
0.1
0.48
0.9
0.4
Basic EPS, GAAP
-4.33
-1.95
-1.16
-1.35
-0.77
-1.1
-1.34
-1.95
-1.45
-1.05
-1.31
-0.66
-0.09
-0.79
0.75
1.35
0.28
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
7.75
9.07
7.85
6.88
6.01
4.63
8.35
8.51
7.51
6.28
6.51
5.97
5.83
7.49
8.01
10.55
10.94
Book Value per Share
7.43
8.85
7.66
6.7
5.84
4.48
8.17
8.37
7.37
6.08
6.37
5.89
5.76
5.1
5.9
8.84
9.36
Tangible Book Value per Share
120
152
169
169
169
169
136
137
156
156
169
187
187
223
223
230
241
Basic Weighted Avg Shares
100
125
149
180
232
153
274
229
270
354
412
463
512
890
1,223
1,400
758
Sales/Revenue/Turnover
-133.64
-185.11
-173.86
-120.02
-75.05
-165.54
-83.46
-134.75
-92.4
-58.09
-40.47
-28.81
-8.15
3.12
14.22
19.07
17.54
Operating Margin (%)
16
46
59
66
67
68
67
58
56
67
67
65
69
136
136
136
67
Depreciation Expense
-113
-205
-196
-176
-145
-237
-199
-265
-160
-201
-171
-103
-29
22
107
208
96
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.77
34.18
14.8
25.34
Effective Tax Rate (%)
-113.67
-164.85
-131.33
-97.49
-62.4
-154.94
-72.5
-115.58
-59.4
-56.86
-41.59
-22.15
-5.62
2.5
8.78
14.88
12.68
Profit Margin (%)
355
455
201
83
61
-25
196
347
108
-24
184
20
72
59
241
1,072
1,105
Working Capital
- -
- -
- -
58
156
278
200
143
121
280
265
221
401
324
238
180
173
LT Debt
1,307
1,530
1,325
1,162
1,017
787
1,090
1,328
1,176
985
1,217
1,116
1,090
1,670
1,788
2,563
2,658
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.19
4.4
8.73
3.32
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.8
4.94
8.45
3.47
Return on Capital (%)
- -
-14.48
-13.75
-14.15
-13.3
-26.29
-21.2
-21.9
-12.78
-18.6
-15.56
-8.8
-2.61
1.61
6.21
9.58
3.68
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
16
16
16
LT Borrowings
- -
- -
- -
LT Finance Leases
180
176
173
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
243
243
243
Market Capitalization
6,355
6,149
6,331

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,259
1,289
1,278
Cash, Cash Equivalents & STI
627
667
585
Accounts Receivable, Net
224
212
251
Inventories
322
325
327
Total Current Liabilities
187
158
173
Payables & Accruals
- -
- -
- -
ST Debt
16
16
16
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.93%
18.6%
43.4%
Free Cash Flow
70.25%
133.07%
84.42%
Net Income, GAAP
17.46%
37.26%
94.12%
Sales/Revenue/Turnover
27.69%
29.74%
14.52%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
276
327
301
319
1,223
2025
317
326
316
442
1,400
2026
331
427
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.26
- -
0.05
0.48
2025
0.23
0.08
0.21
0.38
0.9
2026
0.16
0.24
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Orient Pharma Co., Ltd. (4166.TWO) develops, manufactures and markets generic and specialty pharmaceutical products with a focus on central nervous system disorders, cardiovascular conditions, diabetes and anti-infectives; its core offerings include anti-psychotics and psychostimulants such as extended-release capsules for attention deficit hyperactivity disorder (e.g., Methydur), drugs for Parkinson's disease and sialorrhea including Clonidine/Oxybutynin combinations, muscle relaxants like Carisoprodol, anti-diabetes agents such as Miglitol and Glyburide, blood lipid-lowering medications including Pitavastatin, anti-hyperlipidemia agents, antibiotics like Vancomycin capsules, and advanced drug delivery technologies encompassing multi-stage controlled release systems, transdermal patches, oral disintegrating tablets, sustained release formulations, micro granules, smart semi-solid modified release systems, multiple unit parallel systems (MAPS) and oral osmotic release systems (OROS). The company operates primarily from its GMP-certified facility in Yunlin, Taiwan, approved by regulators including the US FDA, Taiwan FDA, PIC/S, UK, Australia and Japan, serving markets in Taiwan, North America, Southeast Asia including Vietnam and Philippines, China and internationally. Founded in 2008 and headquartered in Taipei, Taiwan, Orient Pharma functions as a key subsidiary of Orient EuroPharma Co., Ltd., concentrating on oral solid dosage forms in neuroscience, autoimmune and cardiovascular therapeutic areas through 505(b)(2) regulatory pathways and global partnerships. Recent developments include expanded licensing for ADHD treatments with Durect Corporation extending to global markets in 2021, technology transfers for lipid-lowering compounds to Beijing-based partners such as Jingxin Pharmaceutical in 2021 to enter mainland China, collaborations with Supernus Pharmaceuticals on CNS products, and advancements in patient-centric innovations highlighted at BIO Asia-Taiwan 2025 featuring multi-phase delivery systems to address unmet needs in adherence and efficacy.